FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2021-09-06
Target enrollment:
Participant gender:
Summary
In this trial chemotherapy regimen FOLFOX with intrahepatic administration of oxaliplatin is
combined with immunotherapy (nivolumab and ipilimumab) for the group of patients with
multiple liver metastasis from colorectal cancer. Investigators hope to increase the
disease-free survival after 3 years from 10 % to 30%.